The aim of the research was a complex analysis of changes in the immune system as well as BCR::ABL1 gene transcript levels after imatinib discontinuation and at loss of MMR in CML patients, who previously achieved stable DMR. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.